Jessie Theuns

List of Publications by Year
in descending order

52 papers	5,109 citations	101543 36 h-index	182427 51 g-index
57 all docs	57 docs citations	57 times ranked	7162 citing authors

#	Article	IF	Citations
1	Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Human Mutation, 2010, 31, 763-780.	2.5	428
2	Locusâ€specific mutation databases for neurodegenerative brain diseases. Human Mutation, 2012, 33, 1340-1344.	2.5	414
3	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
4	APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain, 2006, 129, 2977-2983.	7.6	337
5	Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased AÎ²42 and decreased AÎ²40. Human Mutation, 2006, 27, 686-695.	2.5	306
6	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a caseâ€“control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
7	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
8	A novel presenilin 1 mutation associated with Pick's disease but not Î²â€amyloid plaques. Annals of Neurology, 2004, 55, 617-626.	5.3	210
9	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends in Genetics, 2015, 31, 140-149.	6.7	193
10	Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease. American Journal of Human Genetics, 2006, 78, 936-946.	6.2	173
11	Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Human Molecular Genetics, 1995, 4, 2363-2371.	2.9	171
12	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Human Molecular Genetics, 2005, 14, 3281-3292.	2.9	156
13	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. Archives of Neurology, 2007, 64, 1436.	4.5	143
14	Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.	1.1	119
15	Genetic variability in the mitochondrial serine proteaseHTRA2contributes to risk for Parkinson disease. Human Mutation, 2008, 29, 832-840.	2.5	107
16	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	3.2	94
17	Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. Brain, 2006, 129, 2984-2991.	7.6	76
18	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiology of Aging, 2012, 33, 629.e5-629.e18.	3.1	73

#	Article	IF	Citations
19	Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 2011, 42, 131-141.	2.1	65
20	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Human Mutation, 2009, 30, 1054-1061.	2.5	58
21	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain, 2007, 130, 2277-2291.	7.6	56
22	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	3.1	56
23	Global investigation and meta-analysis of the C9orf72 (G ₄ C ₂) _n repeat in Parkinson disease. Neurology, 2014, 83, 1906-1913.	1.1	56
24	Tau is central in the genetic Alzheimerâ€“frontotemporal dementia spectrum. Trends in Genetics, 2005, 21, 664-672.	6.7	55
25	Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism and Related Disorders, 2011, 17, 135-138.	2.2	54
26	Intraneuronal amyloid Î² and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiology of Aging, 2008, 29, 241-252.	3.1	52
27	APPandBACE1miRNA genetic variability has no major role in risk for Alzheimer disease. Human Mutation, 2009, 30, 1207-1213.	2.5	52
28	The Genetics of Dementia With Lewy Bodies. Archives of Neurology, 2012, 69, 1113-8.	4.5	52
29	Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample. European Journal of Human Genetics, 1999, 7, 801-806.	2.8	49
30	Linkage and Association Studies Identify a Novel Locus for Alzheimer Disease at 7q36 in a Dutch Population-Based Sample. American Journal of Human Genetics, 2005, 77, 643-652.	6.2	48
31	Multi-centre evaluation of a comprehensive preimplantation genetic test through haplotyping-by-sequencing. Human Reproduction, 2019, 34, 1608-1619.	0.9	48
32	Genetic variant in theHSPB1 promoter region impairs the HSP27 stress response. Human Mutation, 2007, 28, 830-830.	2.5	47
33	Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. European Journal of Human Genetics, 2008, 16, 471-479.	2.8	47
34	The Gene Encoding Nicastrin, a Major Î³-Secretase Component, Modifies Risk for Familial Early-Onset Alzheimer Disease in a Dutch Population-Based Sample. American Journal of Human Genetics, 2002, 70, 1568-1574.	6.2	45
35	Alzheimer-associated C allele of the promoter polymorphism -22C>T causes a critical neuron-specific decrease of presenilin 1 expression. Human Molecular Genetics, 2003, 12, 869-877.	2.9	45
36	Amyloid Pathology Influences AÎ²1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2013, 35, 137-146.	2.6	45

#	Article	IF	Citations
37	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinsonâ€™s disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neuroscience Letters, 2016, 629, 160-164.	2.1	34
38	Populationâ€specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	3.9	30
39	Genetic and physical characterization of the early-onset Alzheimer's disease AD3 locus on chromosome 14q24.3. Human Molecular Genetics, 1995, 4, 1355-1364.	2.9	27
40	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. American Journal of Neurodegenerative Disease, 2012, 1, 160-7.	0.1	24
41	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiology of Aging, 2011, 32, 2108.e1-2108.e5.	3.1	23
42	Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. Neurobiology of Aging, 2012, 33, 1844.e11-1844.e13.	3.1	21
43	Comprehensive Genetic and Mutation Analysis of Familial Dementia with Lewy Bodies Linked to 2q35-q36. Journal of Alzheimer's Disease, 2010, 20, 197-205.	2.6	20
44	GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiology of Aging, 2011, 32, 308-312.	3.1	14
45	Alphaâ€synuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	3.9	14
46	Â-Synuclein gene duplications in sporadic Parkinson disease. Neurology, 2008, 70, 7-9.	1.1	13
47	Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopaâ€responsive dystonia. Movement Disorders, 2012, 27, 1451-1456.	3.9	11
48	Mutation analysis of the chromosome 14q24.3 dihydrolipoyl succinyltransferase (DLST) gene in patients with early-onset Alzheimer disease. Neuroscience Letters, 1995, 199, 73-77.	2.1	9
49	Determination of the genomic organization of human presenilin 1 by fiber-FISH analysis and restriction mapping of cloned DNA. Mammalian Genome, 1999, 10, 410-414.	2.2	9
50	TheTNFRSF6 gene is not implicated in familial early-onset Alzheimer's disease. Human Genetics, 2001, 108, 552-553.	3.8	6
51	GIGYF2 in Parkinson's disease: Innocent until proven otherwise. Neurobiology of Aging, 2010, 31, 1072-1074.	3.1	4
52	Agilent Technologies OnePGT solution: External verification on both blastomere and trophectoderm biopsies. Reproductive BioMedicine Online, 2019, 38, e11-e12.	2.4	0